Andes virus is a member of the hantavirus family responsible for the MV Hondius cruise ship outbreak.
The only vaccine against hantaviruses in use is Hantavax which targets Hantaan river virus and Seoul virus, both "old world" hantaviruses, causing different symptoms than "new world" hantaviruses like the Andes virus (https://en.wikipedia.org/wiki/Hantavirus_vaccine)
Moderna has been working on mRNA hantavirus vaccine, though this seems to target old world hantaviruses as well:
Resolves YES if any officially sanctioned vaccine trial in humans occurs before close date, where:
the vaccine has preclinical data suggesting possible efficacy against Andes virus
the trial has testing efficacy against Andes virus among its goals
As @Cactus noted, there was a vaccine tested earlier (https://pubmed.ncbi.nlm.nih.gov/37380156/). This market will only consider trials that happen after market creation (specifically, that the vaccine is administered to humans after market creation, if the trial started or was designed earlier, it still counts).
The results of the trial are not relevant for resolution.
I will not bet on this market.
1,000People are also trading
@Cactus Interesting, I didn't do a very thorough search and so I missed that one. I think that it is typically implicitly assumed that "after market creation" is part of the market criteria and so I won't consider this. Let me know if you've lost any mana based on this discrepancy and I'll be happy to managram it to you.
@unweidly Yes. It seems that you bought 805 YES for M 600, which is now worth ~M320. So an M280 to refund - does that sound fair?